Q2 2026

Filed Aug 6, 2026 · 10-Q · 37 days after period end · 0001104659-26-092065

Q2 2026 · 10-Q

Revenue

$1.63M

−8.3% vs Q2 2025

Net Income

-$21.51M

N/M vs Q2 2025

EPS Diluted

-$0.15

N/M vs Q2 2025

Operating Income-$24,238,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2026	Q2 2025	Q2 2024	Q2 2023
Revenue	$1.63M	$1.78M	$2.77M	$1.87M
Net Income	-$21.51M	-$15.43M	-$10.99M	-$29.57M
EPS Diluted	-$0.15	-$0.13	-$0.15	-$0.42

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR